Search results
Showing 61 to 75 of 1521 results for patients and public
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]
In development Reference number: GID-TA11414 Expected publication date: 10 June 2026
This quality standard covers preventing and controlling infections in hospitals and other secondary care settings that develop because of treatment or from being in a healthcare setting (healthcare-associated infections). It includes monitoring, responsibilities, and policies and procedures in secondary care organisations to reduce the risk of infection in patients, staff and visitors. It describes high-quality care in priority areas for improvement.
View quality statements for QS113Show all sections
Sections for QS113
- Quality statements
- Quality statement 1: Surveillance
- Quality statement 2: Collaborative action
- Quality statement 3: Responsibilities of hospital staff
- Quality statement 4: Planning, design and management of hospital facilities
- Quality statement 5: Admission, discharge and transfer
- About this quality standard
In development Reference number: GID-TA11554 Expected publication date: TBC
This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.
View quality statements for QS167Show all sections
Sections for QS167
- Quality statements
- Quality statement 1: Designing health and wellbeing programmes
- Quality statement 2: Peer and lay roles
- Quality statement 3: Referring people at high risk of type 2 diabetes
- Quality statement 4: Cardiac rehabilitation
- Quality statement 5: Support for people with mental health problems
- Quality statement 6: Physical health checks for people with serious mental illness
- Update information
In development Reference number: GID-TA11220 Expected publication date: TBC
In development Reference number: GID-HST10067 Expected publication date: 19 August 2026
In development Reference number: GID-TA11817 Expected publication date: 09 July 2026
In development Reference number: GID-TA11502 Expected publication date: 02 December 2026
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
Awaiting development Reference number: GID-TA11565 Expected publication date: 21 May 2026
In development Reference number: GID-TA11576 Expected publication date: 18 June 2026
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]
In development Reference number: GID-TA11643 Expected publication date: 18 March 2026
In development Reference number: GID-TA11477 Expected publication date: 12 August 2026
In development Reference number: GID-TA11768 Expected publication date: 03 September 2026
In development Reference number: GID-TA11636 Expected publication date: 26 August 2026
In development Reference number: GID-TA11635 Expected publication date: 26 August 2026